PegIFN and/or Lamivudine in Patients with HBeAg-positive CHB Patients (%) Responses at End of Follow-up (Week 72) HBV DNA <400 copies/mL HBeAg Seroconversion HBV DNA <10 5 copies/mL Normalized ALT PegIFN was statistically significantly better than lamivudine monotherapy for all measures.